

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM452176

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BioPharma Secured Investments III Holdings Cayman LP		11/15/2017	Limited Partnership: CAYMAN ISLANDS
RECEIVING PARTY DATA			
Name:	PaxVax, Inc.		
Street Address:	555 Twin Dolphin Drive		
Internal Address:	Suite 360		
City:	REDWOOD CITY		
State/Country:	CALIFORNIA		
Postal Code:	94065		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	5335613	PAXVAX	
CORRESPONDENCE DATA			
Fax Number:	6179518736		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6179518000		
Email:	jennifer.kagan@morganlewis.com		
Correspondent Name:	Jennifer Kagan, Paralegal		
Address Line 1:	One Federal Street		
Address Line 2:	Morgan, Lewis & Bockius LLP		
Address Line 4:	Boston, MASSACHUSETTS 02110		
ATTORNEY DOCKET NUMBER:	108542-0011		
NAME OF SUBMITTER:	Jennifer Kagan, Paralegal		
SIGNATURE:	/jenniferkagan/		
DATE SIGNED:	11/27/2017		
Total Attachments: 16			
source=PaxVax - IP Release#page1.tif			

CH \$40.00 5335613

source=PaxVax - IP Release#page2.tif
source=PaxVax - IP Release#page3.tif
source=PaxVax - IP Release#page4.tif
source=PaxVax - IP Release#page5.tif
source=PaxVax - IP Release#page6.tif
source=PaxVax - IP Release#page7.tif
source=PaxVax - IP Release#page8.tif
source=PaxVax - IP Release#page9.tif
source=PaxVax - IP Release#page10.tif
source=PaxVax - IP Release#page11.tif
source=PaxVax - IP Release#page12.tif
source=PaxVax - IP Release#page13.tif
source=PaxVax - IP Release#page14.tif
source=PaxVax - IP Release#page15.tif
source=PaxVax - IP Release#page16.tif

TERMINATION OF SECURITY INTEREST IN PATENTS AND TRADEMARKS

WHEREAS, PaxVax, Inc., a Delaware corporation with its principal place of business at 555 Twin Dolphin Drive, Suite 360, Redwood City, CA 94065 (the "Grantor"), is the owner of record or licensee of certain patents, patent applications, trademarks and trademark applications now issued or pending in the United States Patent and Trademark Office; and

WHEREAS, the Grantor entered into a certain Patent Security Agreement dated as of July 25, 2014 (the "Patent Security Agreement"), between the Grantor and BioPharma Secured Investments III Holdings Cayman LP., ("Secured Party"), with respect to those patents and patent applications more particularly described in Schedule I to the Patent Security Agreement, attached hereto as Exhibit A (the "Patents"), a true and correct copy of which was recorded by the United States Patent and Trademark Office on July 30, 2014 at Reel: 033449 Frame: 0733, and later corrected on August 7, 2014, at Reel: 033502 Frame: 0928;

WHEREAS, the Grantor entered into a certain Trademark Security Agreement dated as of July 25, 2014 (the "Trademark Security Agreement"), between the Grantor and Secured Party, with respect to those trademark and trademark applications more particularly described in Schedule 1 to the Trademark Security Agreement, attached hereto as Exhibit B (the "Trademarks"), a true and correct copy of which was recorded by the United States Patent and Trademark Office on July 30, 2014 at Reel: 5333 Frame: 0282, and later corrected on August 1, 2014, at Reel: 5334 Frame: 0808;

WHEREAS, the Secured Party desires to release its security interest in the Patents and Trademarks and terminate the Patent Security Agreement and the Trademark Security Agreement;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Secured Party hereby:

1. Releases and reassigns to the Grantor any and all liens, security interests, right, title and interest of Secured Party pursuant to the Patent Security Agreement in the patents and patent applications more particularly described on Exhibit A, without recourse or representation or warranty, express or implied; and
2. Releases and reassigns to the Grantor any and all liens, security interests, right, title and interest of Secured Party pursuant to the Trademark Security Agreements in the trademarks and trademark applications more particularly described on Exhibit B, without recourse or representation or warranty, express or implied; and
3. Authorizes and requests the Commissioner of Patents and Trademarks of the United States of America to note and record the existence of the release hereby given.

IN WITNESS WHEREOF, Secured Party has caused this Termination of Security Interest in Trademarks and Patents to be signed by its duly authorized representative as of the date set forth below.

BIOPHARMA SECURED INVESTMENTS III
HOLDINGS CAYMAN LP

By: 

Name: Pedro Gonzalez de Cosio

Title: Managing Member

By: Pharmacis Advisors, LP
Its Investment Manager

By: Pharmacis Management I, LLC
Its General Partner

**EXHIBIT A
PATENTS**

SCHEDULE I
TO
PATENT SECURITY AGREEMENT

Patent Registrations

<u>Assigned to PaxVax</u>					
<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
PAXV-001					
Not Published	US 61/024,164 2008-01-28	Henderson, Daniel R. PaxVax	ORAL ADENOVIRUS- BASED	EXPIRED	None
PAXV-003					
Not Published	US 61/086,438 2008-08-05	Shabram, Paul	STABLE, DRY, IMMUNE- MASKED ADENOVIRAL VECTOR VACCINES	EXPIRED	None
PAXV-004					
Not Published	US 61/230,617 2009-07-31	Mayall, Timothy P. Alexander, Jeff PAXVAX, INC. (024628/0567)	ADENOVIRAL- BASED VACCINES	EXPIRED	
US 2011/0123564 A1 2011-05-26	US 61/230,617 2009-07-31 US 12/847,767 2010-07-30	Mayall, Timothy P. Alexander, Jeff PAXVAX, INC. (025351/0357)	ADENOVIRAL- BASED VECTORS	ALLOWED Expires: 2030-07- 30 (projected) 2014-06-06 Notice of allowance mailed	AU 2010278797 A1 AU 2010278797 (Pending) BR 112012008060-1 (Pending) CA 2,769,752 A1 CA 2,769,752 (Pending) CN 102549152 A CN 201080044581.9 (Pending)

<u>Assigned to PaxVax</u>					
<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
					EP 2459716 A1 <i>EP 10805122.8</i> (Pending) <i>IN</i> <i>1827/DELNP/2012</i> (Pending) JP 2013-501001 A <i>JP 2012-523098</i> (Pending) KR 20120052369 A <i>KR 10-2012-7005335</i> (Pending) MX 2012001404 A <i>MX</i> <i>MX/a/2012/001404</i> (Pending) RU 2012107702 A <i>RU 2012107702</i> (Pending) WO 2011/014794 A1 <i>PCT/US2010/043951</i> (Closed)
PAXV-010					
Not Published	US 61/446,309 2011-02-24	Patel, Amish A. Shabram, Paul W. PAXVAX, INC. (027521/0615)	FORMULATIONS USEFUL FOR SPRAY DRYING VACCINES	EXPIRED	
Not Published	US	Patel, Amish	FORMULATIONS	ABANDONED	

Assigned to PaxVax

<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
	61/446,309 2011-02-24 US 13/369,021 2012-02-08	A. Shabram, Paul W.	USEFUL FOR SPRAY DRYING VACCINES		
US 2012/0219590 A1 2012-08-30	US 61/446,309 2011-02-24 US 13/404,950 2012-02-24	Patel, Amish A. Shabram, Paul W. PAXVAX, INC. (028181/0142)	FORMULATIONS USEFUL FOR SPRAY DRYING VACCINES	PENDING Expires: 2032-02-24 (projected) 2014-07-01 Final Rejection mailed	AU 2012222150 A1 AU 2012222150 (Pending) CA 2,828,248 A1 CA 2,828,248 (Pending) EP 2678020 A2 EP 12749476.3 (Pending) RU 2013143149 (Pending) WO 2012/116280 A2 PCT/US2012/026518 (Closed)
PAXV-011					
Not Published	US 61/618,016 2012-03-30	Mayall, Timothy P. PAXVAX, INC. (029107/0146)	ADENOVIRAL- BASED VECTORS	EXPIRED	None
PAXV-012					
Not Published	US 61/492,597 2011-06-02	Patel, Amish A. Shabram, Paul W. PAXVAX,	NANOFILM COATING FOR ADENOVIRUS	EXPIRED	

Assigned to PaxVax

<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
		INC. (027521/0723)			
US 2012/0308660 A1 2012-12-06	US 61/492,597 2011-06-02 US 13/486,949 2012-06-01	Patel, Amish A. Shabram, Paul W. PAXVAX, INC. (028337/0900)	NANOCOATINGS FOR BIOLOGICAL MATERIALS	PENDING Expires: 2032-06-01 (projected) 2014-04-16 Requirement for Restriction/Election mailed	WO 2012/167144 A1 PCT/US2012/040546 (Closed)
PAXV-013					
Not Published	US 61/412,829 2010-11-12	Monath, Thomas P.	CHEMICALLY INACTIVATED AND REPLICATION- INCOMPETENT CHIMERIC DENGUE VIRUS AS VACCINES FOR PREVENTION OF DENGUE FEVER AND SEVERE DENGUE	EXPIRED	
Not Published	US 61/439,225 2011-02-03	Monath, Thomas P.	CHEMICALLY INACTIVATED AND REPLICATION- INCOMPETENT CHIMERIC DENGUE VIRUS AS VACCINES FOR PREVENTION OF DENGUE FEVER	EXPIRED	

Assigned to PaxVax

<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
			AND SEVERE DENGUE		
Not Published	US 61/499,591 2011-06-21	Monath, Thomas P. Vasilakis, Nikos PAXVAX, INC. (026565/0200, 027202/0388)	CHEMICALLY INACTIVATED AND REPLICATION- INCOMPETENT CHIMERIC DENGUE VIRUS AS VACCINES FOR PREVENTION OF DENGUE FEVER AND SEVERE DENGUE	EXPIRED	
Not Published	US 61/522,295 2011-08-11	Monath, Thomas P. Vasilakis, Nikos PAXVAX, INC. (027202/0388, no assignment recorded for Nikos Vasilakis)	CHEMICALLY INACTIVATED AND REPLICATION- INCOMPETENT CHIMERIC DENGUE VIRUS AS VACCINES FOR PREVENTION OF DENGUE FEVER AND SEVERE DENGUE	EXPIRED	
US 2012/0294889 A1 2012-11-22	US 61/412,829 2010-11-12 US 61/439,225 2011-02-03 US	Monath, Thomas P. Vasilakis, Nikos PAXVAX, INC. (028137/0060)	CHIMERIC FLAVIVIRUS VACCINES	ABANDONED	WO 2012/065105 A2 PCT/US2011/060436 (Closed)

<u>Assigned to PaxVax</u>					
<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
	61/499,591 2011-06-21 US 61/522,295 2011-08-11 US 13/294,954 2011-11-11				
PAXV-014					
Not Published	US 61/635,179 2012-04-18	Patel, Amish Bessette, Shannyn Shabram, Paul PAXVAX, INC. (029040/0552)	FORMULATION FOR VACCINE STABILIZATION	EXPIRED	None
PAXV-015					
Not Published	US 61/645,542 2012-05-10	Monath, Thomas P. Vasilakis, Nikos Volkova, Zhenia PAXVAX, INC. (029106/0615)	CHIMERIC FLAVIVIRUS VACCINES	EXPIRED	None

<u>In Licensed By PaxVax</u>					
<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
PAXV-005					
US 2008/0187557	US 60/670,826	Sambhara, Suryaprakash	VACCINE AGAINST	ABANDON ED	AU 2006236910 A1 AU 2006236910 B2

In Licensed By PaxVax

<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
A1 2008-08-07	2005-04-11 PCT/US20 06/013384 2006-04-10 US 11/911,189 2007-10-10	Katz, Jacqueline Hoelscher, Mary Mittal, Suresh K. Bangari, Dinesh S. PURDUE RESEARCH FOUNDATION ; THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (019184/0339, 021162/0260, 019183/0772, 021162/0294)	PANDEMIC STRAINS OF INFLUENZA VIRUSES		AU 2006236910 (Abandoned) BR PI0609362 A2 BR PI 0609362-0 (Abandoned) CA 2,604,732 A1 CA 2,604,732 (Pending) CN 101193655 A CN 200680020766.X (Pending) EP 1877088 A2 EP 06769811.8 (Abandoned) IL 186611 (Abandoned) IN 23/2008 IN 4150/KOLNP/2007 (Pending) KR 10-2008-0052509 A KR 10-2007-7026275 (Abandoned) WO 2006/113214 A2 PCT/US2006/013384 (Closed)
US 8,163,545 B2 2012-04-24 US 2010/0158939 A1 2010-06-24	US 60/670,826 2005-04-11 PCT/US20 06/013384 2006-04-10 US 11/911,189 2007-10-10	Sambhara, Suryaprakash Katz, Jacqueline Hoelscher, Mary Mittal, Suresh K. Bangari, Dinesh S. PURDUE RESEARCH FOUNDATION	VACCINE AGAINST PANDEMIC STRAINS OF INFLUENZA VIRUSES	ISSUED Expires: 2026-04-10 1 st fee due 2016-04-25 2 nd fee due 2020-04-24 3 rd fee due	AU 2006236910 A1 AU 2006236910 B2 AU 2006236910 (Abandoned) BR PI0609362 A2 BR PI 0609362-0 (Abandoned) CA 2,604,732 A1 CA 2,604,732 (Pending)

In Licensed By PaxVax

<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
	US 12/646,078 2009-12-23	THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (023696/0676, 023696/0665)		2024-04-24	CN 101193655 A CN 200680020766.X (Pending) EP 1877088 A2 EP 06769811.8 (Abandoned) IL 186611 (Abandoned) IN 23/2008 IN 4150/KOLNP/2007 (Pending) KR 10-2008-0052509 A KR 10-2007-7026275 (Abandoned) WO 2006/113214 A2 PCT/US2006/013384 (Closed)
PAXV-007					
WO 2006/083984 A1 2006-08-10	US 60/649,249 2005-02-01 US 60/697,655 2005-07-07 US 60/752,268 2005-12-21 PCT/US2006/003601 2006-02-01	Schiller, John T. Pastrana, Diana V. Gambhira, Ratish Lowy, Douglas R. Roden, Richard B.S. THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH	PAPILLOMAVIRUS L2 N-TERMINAL PEPTIDES FOR THE INDUCTION OF BROADLY CROSS-NEUTRALIZING ANTIBODIES	CLOSED	AU 2006210792 A1 AU 2006210792 B2 AU 2006210792 (Granted) BR PI0607097 A2 BR PI 0607097-3 (Pending) CA 2,596,698 A1 CA 2,596,698 (Pending) CN 101193653 A CN 101193653 B CN 200680011079.1 (Granted) EP 1853307 A1 EP 06734177.6 (Pending)

In Licensed By PaxVax

<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
		AND HUMAN SERVICES; THE JOHNS HOPKINS UNIVERSITY			IN 35/2007 <i>IN 6219/DELNP/2007</i> (Pending) JP 5224821 B2 JP 2008-530010 A <i>JP 2007-554194</i> (Granted)
US 8,404,244 B2 2013-03-26 US 2009/0047301 A1 2009-02-19	US 60/649,249 2005-02-01 US 60/697,655 2005-07-07 US 60/752,268 2005-12-21 PCT/US2006/003601 2006-02-01 US 11/883,495 2008-05-13	Schiller, John T. Pastrana, Diana V. Gambhira, Ratish Lowy, Douglas R. Roden, Richard B.S. THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; THE JOHNS HOPKINS UNIVERSITY (019555/0491, 021103/0253, 019555/0140, 021103/0257)	PAPILLOMAVIRUS L2 N-TERMINAL PEPTIDES FOR THE INDUCTION OF BROADLY CROSS-NEUTRALIZING ANTIBODIES	ISSUED Expires: 2028-03-23 (2026-02-01 + 781 days) 1 st fee due 2017-03-27 2 nd fee due 2021-03-26 3 rd fee due 2025-03-26	AU 2006210792 A1 AU 2006210792 B2 <i>AU 2006210792</i> (Granted) BR PI0607097 A2 <i>BR PI 0607097-3</i> (Pending) CA 2,596,698 A1 <i>CA 2,596,698</i> (Pending) CN 101193653 A CN 101193653 B <i>CN 200680011079.1</i> (Granted) EP 1853307 A1 <i>EP 06734177.6</i> (Pending) IN 35/2007 <i>IN 6219/DELNP/2007</i> (Pending) JP 5224821 B2 JP 2008-530010 A <i>JP 2007-554194</i> (Granted)
US 2013/0177585 A1 2013-07-11	US 60/649,249 2005-02-01	Schiller, John T. Pastrana, Diana V. Gambhira,	PAPILLOMAVIRUS L2 N-TERMINAL PEPTIDES FOR	PENDING Expires: 2026-02-01	AU 2006210792 A1 AU 2006210792 B2 <i>AU 2006210792</i> (Granted)

In Licensed By PaxVax

<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
	US 60/697,655 2005-07-07 US 60/752,268 2005-12-21 PCT/US20 06/003601 2006-02-01 US 11/883,495 2008-05-13 US 13/772,893 2013-02-21	Ratish Lowy, Douglas R. Roden, Richard B.S. THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; THE JOHNS HOPKINS UNIVERSITY (Parent)	THE INDUCTION OF BROADLY CROSS- NEUTRALIZING ANTIBODIES	(projected) 2014-06-19 Final Rejection mailed	BR P10607097 A2 BR P10607097-3 (Pending) CA 2,596,698 A1 CA 2,596,698 (Pending) CN 101193653 A CN 101193653 B CN 200680011079.1 (Granted) EP 1853307 A1 EP 06734177.6 (Pending) IN 35/2007 IN 6219/DELNP/2007 (Pending) JP 5224821 B2 JP 2008-530010 A JP 2007-554194 (Granted)
PAXV-008					
US 2006/0115456 A1 2006-06-01	US 60/629,722 2004-11-18 US 11/282,319 2005-11-17	Peng, Bo Voltan, Rebecca Ensoli, Barbara Robert-Guroff, Marjorie ISTITUTO SUPERIORE DI SANITA; THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE	REPLICATION- COMPETENT ADENOVIRAL VECTORS	PENDING Expires: 2025-11-17 (projected) 2014-07-03 Final Rejection mailed	None

In Licensed By PaxVax

<u>Patent / Publication</u>	<u>Priority / Application</u>	<u>Inventors / Assignee</u>	<u>Title / Current Claims</u>	<u>Status</u>	<u>Foreign Patent Family</u>
		DEPARTMENT OF HEALTH AND HUMAN SERVICES (017238/0794, 017238/0783)			

**EXHIBIT B
TRADEMARKS**

SCHEDULE I
TO
TRADEMARK SECURITY AGREEMENT

Trademark Registrations

Mark	Country	App/Reg No.	App/Reg Date	Goods and Services	Status
PAXVAX	United States	App: 86047042	App: 8/23/2013	Class 05: Pharmaceuticals for use in the prevention and treatment of infections conditions, and disorders and diseases related to the gastrointestinal tract, cardiovascular system, metabolic system, respiratory system, and central nervous system; vaccines	Published
PAXVYB	United States	App: 86205410	App: 2/26/2014	Class 05: Pharmaceuticals; pharmaceuticals for use in the prevention and treatment of infections conditions, disorders and diseases; vaccines	Filed
PROTEVRIO	United States	App: 86225234	App: 3/19/2014	Class 05: Pharmaceuticals; pharmaceuticals for use in the prevention and treatment of infectious conditions, disorders and diseases; vaccines	Filed
TREKVAX	United States	86037640	8/14/2013	Class 05: Pharmaceuticals for use in the prevention and treatment of infections conditions, and disorders and diseases related to the gastrointestinal tract, cardiovascular system, metabolic system, respiratory system, and central nervous system; vaccines	Allowed
TREKPAK	USA	86/037,622	8/14/2013	Class 05: Pharmaceuticals; vaccines	Published; Abandoned
VAXCHORA	United States	App: 86205531	App: 2/26/2014	Class 05: Pharmaceuticals; pharmaceuticals for use in the prevention and treatment of infections conditions, disorders and diseases	Filed
VIBROGARDE	United States	App: 86037630	App: 8/14/2013	Class 05: Pharmaceuticals for use in the prevention and treatment of infections conditions, and disorders and diseases related to the gastrointestinal tract, cardiovascular system, metabolic	Allowed

				system, respiratory system, and central nervous system; vaccines	
VOYAPAK	United States	App: 86037636	App: 8/14/2013	Class 05: Pharmaceuticals for use in the prevention and treatment of infections conditions, and disorders and diseases related to the gastrointestinal tract, cardiovascular system, metabolic system, respiratory system, and central nervous system; vaccines	Allowed
VOYASAN	United States	App: 86205404	App: 2/26/2014	Class 05: Pharmaceuticals; pharmaceuticals for use in the prevention and treatment of infections conditions, disorders and diseases; vaccines	Filed

[ACKNOWLEDGEMENT OF GRANTOR FOR TRADEMARK SECURITY AGREEMENT]